GO:0004814 arginine-tRNA ligase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004814 arginine-tRNA ligase activity is the molecular function that attaches L-arginine to its cognate tRNA(Arg) using ATP, producing L-arginyl-tRNA(Arg), AMP and diphosphate.
• The reaction is catalyzed by arginyl-tRNA synthetase (RARS1 in humans), a class I aminoacyl-tRNA synthetase that requires inter-domain communication for tRNA-dependent arginine activation.
• RARS1 is part of the multi-synthetase complex, linking arginine charging to broader translational and non-translational signaling networks.
• Biallelic RARS1 variants cause hypomyelinating leukodystrophy and can present within the Leigh syndrome spectrum, making this GO term directly relevant to neurogenetic disease.
• Arginyl-tRNA synthetases functionally interplay with arginyltransferase (ATE1), connecting arginine charging to post-translational arginylation.
• Loss or dysregulation of arginine-tRNA ligase activity can trigger ribosome-associated quality control and stress responses during amino acid limitation.
Description
GO:0004814 arginine-tRNA ligase activity is a molecular function defined in the Gene Ontology as the catalysis of the reaction ATP + L-arginine + tRNA(Arg) = AMP + diphosphate + L-arginyl-tRNA(Arg). This activity is essential for protein synthesis because it ensures that arginine is correctly paired with its cognate tRNA before ribosomal decoding. The enzyme responsible, arginyl-tRNA synthetase (RARS1 in humans), belongs to the class I aminoacyl-tRNA synthetases and uses a two-step mechanism that requires inter-domain communication for tRNA-dependent arginine activation. Structural studies of the yeast ortholog have revealed how L-arginine is recognized within the active site, providing a framework for understanding disease-causing mutations. For researchers, GO:0004814 matters because it sits at the intersection of translation, cellular stress responses, and human disease. RARS1 is one of the aminoacyl-tRNA synthetases that can assemble into the multi-synthetase complex, a hub that extends beyond translation. Mutations in RARS1 cause hypomyelinating leukodystrophy and can also present within the Leigh syndrome spectrum, underscoring the clinical importance of this activity. In addition, arginyl-tRNA synthetases functionally interplay with arginyltransferase, linking arginine charging to post-translational arginylation. When amino acid availability is limited, aberrant protein production can engage ribosome-associated quality control, further connecting this activity to proteostasis. This article integrates the QuickGO definition with verified PubMed literature to provide a research-grade overview of arginine-tRNA ligase activity, its genes, mechanisms, disease links, and experimental models. It is intended for scientists who need a precise, citable summary for grant writing, target evaluation, or experimental design.
arginine-tRNA ligase activity At A Glance
| GO ID | GO:0004814 |
|---|---|
| GO term | arginine-tRNA ligase activity |
| Ontology | molecular_function |
| Synonym | arginine-tRNA synthetase activity; arginyl-tRNA synthetase activity; arginine translase activity; arginyl-transfer RNA synthetase activity |
| Major function | Catalyzes the attachment of L-arginine to tRNA(Arg) using ATP, producing L-arginyl-tRNA(Arg), AMP and diphosphate |
| Enzyme class | Class I aminoacyl-tRNA synthetase |
| Human gene | RARS1 (arginyl-tRNA synthetase 1) |
| Complex membership | Can associate with the multi-synthetase complex |
| Related activity | Functional interplay with arginyltransferase (ATE1) |
What Is GO:0004814?
In simple terms, GO:0004814 describes the enzyme activity that loads the amino acid arginine onto its matching tRNA molecule. The official definition states: Catalysis of the reaction: ATP + L-arginine + tRNA(Arg) = AMP + diphosphate + L-arginyl-tRNA(Arg). This is a two-step aminoacylation reaction in which arginine is first activated with ATP to form an aminoacyl-adenylate intermediate, and then transferred to the 3' end of tRNA(Arg). The activity is performed by arginyl-tRNA synthetase, a class I aminoacyl-tRNA synthetase, and requires inter-domain communication for efficient tRNA-dependent activation of arginine.
Why Is arginine-tRNA ligase activity Important in Cell Biology?
Arginine-tRNA ligase activity is fundamental to translating the genetic code because it ensures that arginine is incorporated at the correct positions in newly synthesized proteins. Beyond translation, the enzyme participates in the multi-synthetase complex, which integrates aminoacylation with diverse cellular signaling functions. Defects in this activity cause severe neurological disease, including RARS1-related hypomyelinating leukodystrophy and Leigh syndrome spectrum presentations. The activity also intersects with post-translational arginylation through functional interplay with arginyltransferase, and with ribosome-associated quality control during amino acid limitation. Consequently, GO:0004814 is a high-value target for studies of translation, neurodevelopment, and proteostasis.
• Essential for protein synthesis: provides charged L-arginyl-tRNA(Arg) for ribosomal translation.
• Maintains translational fidelity by pairing arginine with its cognate tRNA.
• Links to the multi-synthetase complex, a hub beyond translation.
• Causes RARS1-related hypomyelinating leukodystrophy when mutated.
• Can present within the Leigh syndrome spectrum, a mitochondrial-neurological disorder.
• Interplays functionally with arginyltransferase, affecting post-translational arginylation.
• Engages ribosome-associated quality control under amino acid limitation.
• Provides a target for CRISPR knockout, point-mutation, and knock-in disease modeling.
• Relevant to cancer biology through tRNA-derived fragments and ferroptosis regulation.
Molecular Mechanism of arginine-tRNA ligase activity
Substrate binding and arginine activation
In simple terms: The enzyme first grabs arginine and ATP to make a high-energy intermediate.
Arginyl-tRNA synthetase binds L-arginine and ATP in its catalytic site. The enzyme activates arginine by forming an aminoacyl-adenylate intermediate, releasing diphosphate. This step requires inter-domain communication for efficient tRNA-dependent activation of arginine. Structural analysis of the yeast enzyme has defined the specific residues that recognize L-arginine, providing a molecular basis for substrate specificity.
tRNA recognition and aminoacyl transfer
In simple terms: The enzyme then transfers the activated arginine onto the correct tRNA.
After activation, the enzyme transfers L-arginine to the 3' end of tRNA(Arg), forming L-arginyl-tRNA(Arg) and releasing AMP. This step depends on correct recognition of tRNA(Arg) identity elements. The reaction is part of the class I aminoacyl-tRNA synthetase mechanism, which typically charges the 2'-OH of the terminal adenosine before transesterification. The overall reaction is ATP + L-arginine + tRNA(Arg) = AMP + diphosphate + L-arginyl-tRNA(Arg).
Inter-domain communication and conformational changes
In simple terms: Different parts of the enzyme must talk to each other to work properly.
The tRNA-dependent activation of arginine by arginyl-tRNA synthetase requires inter-domain communication, meaning that the catalytic site and tRNA-binding domains must coordinate their movements. This communication ensures that arginine activation is coupled to the presence of the correct tRNA, preventing wasteful ATP consumption. Structural studies of the yeast enzyme have revealed how L-arginine recognition is achieved within this dynamic architecture.
Integration with the multi-synthetase complex
In simple terms: The enzyme can join a larger complex that does more than just translation.
Aminoacyl-tRNA synthetases, including arginyl-tRNA synthetase, can assemble into the multi-synthetase complex, which extends their functions beyond translation. This complex provides a platform for channeling charged tRNAs to the ribosome and for non-translational signaling. The association of arginyl-tRNA synthetase with this complex links GO:0004814 to broader cellular regulation.
Functional interplay with arginyltransferase
In simple terms: The enzyme also connects to a system that adds arginine to proteins after they are made.
Arginyl-tRNA synthetases functionally interplay with arginyltransferase (ATE1), the enzyme responsible for post-translational arginylation. This interplay means that arginine charging can influence the availability of arginyl-tRNA for arginylation reactions. The relationship between these two activities is an active area of research linking translation to post-translational modification.
Key Genes Involved in GO:0004814 arginine-tRNA ligase activity
The following genes and proteins are directly or functionally associated with arginine-tRNA ligase activity (GO:0004814) based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| RARS1 | Human arginyl-tRNA synthetase; catalyzes arginine-tRNA ligase activity | Mutations cause hypomyelinating leukodystrophy and Leigh syndrome spectrum |
| RARS2 | Mitochondrial arginyl-tRNA synthetase | Related to mitochondrial translation and neurological disease |
| ATE1 | Arginyltransferase; transfers arginine to proteins | Functional interplay with arginyl-tRNA synthetases |
| AARS1 | Alanyl-tRNA synthetase; component of multi-synthetase complex | Part of the complex that includes arginyl-tRNA synthetase |
| KARS1 | Lysyl-tRNA synthetase; component of multi-synthetase complex | Multi-synthetase complex member |
| MARS1 | Methionyl-tRNA synthetase; component of multi-synthetase complex | Multi-synthetase complex member |
| EPRS1 | Glutamyl-prolyl-tRNA synthetase; component of multi-synthetase complex | Multi-synthetase complex member |
| IARS1 | Isoleucyl-tRNA synthetase; component of multi-synthetase complex | Multi-synthetase complex member |
| LARS1 | Leucyl-tRNA synthetase; component of multi-synthetase complex | Multi-synthetase complex member |
| QARS1 | Glutaminyl-tRNA synthetase; component of multi-synthetase complex | Multi-synthetase complex member |
| RPS3 | Ribosomal protein; part of the small subunit | Ribosome-associated quality control under amino acid limitation |
| RPL4 | Ribosomal protein; part of the large subunit | Ribosome-associated quality control under amino acid limitation |
| GCN2 (EIF2AK4) | Amino acid starvation sensor kinase | Links amino acid limitation to ribosome-associated quality control |
| tRF-E | tRNA-derived fragment | Promotes ferroptosis in hepatocellular carcinoma |
| GPX4 | Glutathione peroxidase 4; ferroptosis regulator | Ferroptosis pathway linked to tRNA-derived fragments |
| SLC7A11 | Cystine/glutamate transporter; ferroptosis regulator | Ferroptosis pathway linked to tRNA-derived fragments |
How Is arginine-tRNA ligase activity Regulated?
Arginine-tRNA ligase activity is regulated at multiple levels. The enzyme requires inter-domain communication for tRNA-dependent activation of arginine, meaning that conformational coupling regulates catalytic efficiency. Its association with the multi-synthetase complex provides a platform for coordinated regulation of aminoacylation and non-translational functions. Under amino acid limitation, ribosome-associated quality control pathways are engaged to handle aberrant protein production, indirectly reflecting the status of aminoacyl-tRNA charging. Additionally, functional interplay with arginyltransferase suggests that the availability of arginyl-tRNA for arginylation is regulated in coordination with protein synthesis.
arginine-tRNA ligase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| RARS1 | Hypomyelinating leukodystrophy | Knockout or point-mutation knock-in in neuronal cell lines |
| RARS2 | Leigh syndrome spectrum | Mitochondrial function assays in patient fibroblasts |
| ATE1 | Post-translational arginylation | Overexpression and knockout models to study interplay |
| tRF-E | Hepatocellular carcinoma ferroptosis | Cancer cell lines with tRNA fragment overexpression |
| GCN2 (EIF2AK4) | Amino acid limitation response | Knockout models to study ribosome quality control |
RARS1-related hypomyelinating leukodystrophy
Biallelic mutations in RARS1, the gene encoding human arginyl-tRNA synthetase, cause hypomyelinating leukodystrophy, a neurological disorder characterized by impaired myelin formation. The spectrum of RARS1-related disease continues to expand, with variable clinical presentations. This directly links GO:0004814 to human neurogenetic disease.
Leigh syndrome spectrum
Nuclear gene-encoded Leigh syndrome spectrum disorders include defects in mitochondrial aminoacyl-tRNA synthetases such as RARS2, which is related to arginine-tRNA ligase activity. These conditions highlight the importance of arginine charging for mitochondrial translation and energy metabolism.
Cancer and ferroptosis
The tRNA-derived fragment tRF-E promotes ferroptosis in hepatocellular carcinoma to suppress tumor progression. Although this fragment is not the enzyme itself, it connects tRNA biology and arginine-related pathways to cancer cell death mechanisms, suggesting that dysregulated tRNA processing can influence tumor biology.
Proteostasis and amino acid stress
Ribosome-associated quality control of aberrant protein production during amino acid limitation is a key stress response that intersects with aminoacyl-tRNA charging. When arginine-tRNA ligase activity is compromised, cells may activate quality control pathways to manage translation defects.
From arginine-tRNA ligase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of RARS1 cause translational defects? | CRISPR knockout of RARS1 in HEK293 or neuronal cells |
| Do disease-associated RARS1 mutations impair charging? | Point-mutation knock-in of patient variants |
| Can wild-type RARS1 rescue the phenotype? | Knock-in of tagged RARS1 for rescue and localization |
| Does RARS1 overexpression affect arginylation? | Overexpression of RARS1 with ATE1 readouts |
| How does amino acid limitation affect charging? | Knockout of GCN2 combined with amino acid starvation |
| What is the role of tRNA fragments in cancer? | Overexpression of tRF-E in hepatocellular carcinoma cells |
How to Study the arginine-tRNA ligase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Aminoacylation assay | Formation of L-arginyl-tRNA(Arg) | Enzyme kinetics and mutant validation |
| Ribo-seq | Ribosome occupancy and translation efficiency | Detecting stalling under amino acid limitation |
| RNA-seq | Transcript abundance changes | Stress response profiling |
| Proteomics | Protein arginylation status | Interplay with ATE1 |
| Fluorescence microscopy | Subcellular localization of RARS1 | Multi-synthetase complex assembly |
| CRISPR knockout screening | Gene essentiality and synthetic lethality | Identifying modifiers of RARS1 phenotype |
| tRNA sequencing | tRNA expression and modification | tRNA fragment biology in cancer |
Aminoacylation assays
Direct measurement of arginine-tRNA ligase activity can be performed using radioactive or fluorescent aminoacylation assays that quantify the formation of L-arginyl-tRNA(Arg) from ATP, L-arginine, and tRNA(Arg). These assays are essential for validating the functional impact of RARS1 mutations.
Ribo-seq and RNA-seq
Ribosome profiling (Ribo-seq) can reveal changes in translation efficiency and codon-specific stalling when arginine-tRNA ligase activity is perturbed. RNA-seq complements this by measuring transcript-level changes in response to amino acid limitation or RARS1 knockout.
Proteomics and arginylation detection
Mass spectrometry-based proteomics can identify proteins with altered arginylation status when RARS1 or ATE1 is manipulated. This approach connects arginine-tRNA ligase activity to post-translational modification networks.
Imaging and cellular localization
Fluorescence microscopy of tagged RARS1 can reveal its subcellular localization and its incorporation into the multi-synthetase complex. Live-cell imaging can track the dynamics of tRNA charging under stress.
How CRISPR Can Be Used to Study GO:0004814 arginine-tRNA ligase activity
Knockout
CRISPR knockout of RARS1 can be used to eliminate arginine-tRNA ligase activity and study the consequences for translation, cell viability, and stress responses. Knockout models are valuable for validating disease mechanisms and identifying compensatory pathways.
Point Mutation
Point-mutation knock-in of patient-specific RARS1 variants allows researchers to dissect which mutations impair arginine charging and cause hypomyelinating leukodystrophy. These models preserve endogenous regulation and are ideal for genotype-phenotype studies.
Knock-in
Tagged knock-in of RARS1 (e.g., with GFP or FLAG) enables visualization and immunoprecipitation of the endogenous enzyme, facilitating studies of its localization and complex assembly. Knock-in of rescue constructs can confirm that the observed phenotypes are due to loss of arginine-tRNA ligase activity.
Overexpression
Overexpression of RARS1 or its disease variants can be used to test gain-of-function effects and interactions with arginyltransferase. Overexpression models are also useful for biochemical purification and structural studies.
How EDITGENE Supports arginine-tRNA ligase activity Research
Researchers studying arginine-tRNA ligase activity-related genes often need to determine whether a candidate gene is causally involved in translation, neurological disease, or stress responses. EDITGENE provides CRISPR-based cell model services that enable precise manipulation of RARS1 and related genes, from complete knockout to subtle point mutations, supporting mechanistic and translational research.
Contact EDITGENE today to design your custom CRISPR model for arginine-tRNA ligase activity research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| DALRD3 Knockout HEK293 Cell Line | EDJ-KQ13092 | Human | 55152 | Details Get a Quote |
| DALRD3 Knockout A-549 Cell Line | EDJ-KQ42380 | Human | 55152 | Details Get a Quote |
| DALRD3 Knockout HCT 116 Cell Line | EDJ-KQ42381 | Human | 55152 | Details Get a Quote |
| DALRD3 Knockout HeLa Cell Line | EDJ-KQ42382 | Human | 55152 | Details Get a Quote |
Frequently Asked Questions About arginine-tRNA ligase activity
What is arginine-tRNA ligase activity?
It is the molecular function defined by GO:0004814, catalyzing the reaction ATP + L-arginine + tRNA(Arg) = AMP + diphosphate + L-arginyl-tRNA(Arg).
What genes are involved in arginine-tRNA ligase activity?
The primary human gene is RARS1, which encodes arginyl-tRNA synthetase; RARS2 encodes the mitochondrial form, and ATE1 functionally interplays with this activity.
What diseases are linked to arginine-tRNA ligase activity?
Mutations in RARS1 cause hypomyelinating leukodystrophy, and related defects can present within the Leigh syndrome spectrum.
How is arginine-tRNA ligase activity regulated?
It is regulated by inter-domain communication, association with the multi-synthetase complex, and interplay with arginyltransferase.
What is the reaction catalyzed by arginine-tRNA ligase?
The reaction is ATP + L-arginine + tRNA(Arg) = AMP + diphosphate + L-arginyl-tRNA(Arg).
Why is arginine-tRNA ligase important for protein synthesis?
It provides the charged L-arginyl-tRNA(Arg) needed for accurate incorporation of arginine during ribosomal translation.
What cell models are used to study arginine-tRNA ligase activity?
CRISPR knockout, point-mutation knock-in, tagged knock-in, and overexpression models in neuronal or cancer cell lines are commonly used.
How does amino acid limitation affect arginine-tRNA ligase activity?
Amino acid limitation can trigger ribosome-associated quality control of aberrant protein production, indirectly reflecting charging status.
Is arginine-tRNA ligase activity involved in cancer?
tRNA-derived fragments such as tRF-E promote ferroptosis in hepatocellular carcinoma, linking tRNA biology to cancer suppression.
What methods measure arginine-tRNA ligase activity?
Aminoacylation assays, Ribo-seq, RNA-seq, proteomics, and fluorescence microscopy are used to measure activity and its downstream effects.
Conclusion
GO:0004814 arginine-tRNA ligase activity is a core molecular function that ensures accurate arginine incorporation into proteins and connects translation to cellular stress responses, post-translational arginylation, and human neurological disease. The enzyme RARS1 and its partners are well-documented in the literature, with clear links to hypomyelinating leukodystrophy and Leigh syndrome spectrum disorders. Understanding this activity requires integrating structural, biochemical, and genetic approaches, and CRISPR-based models are powerful tools for dissecting its roles in health and disease.
References
- 1. Adam MP et al.. 1993. Nuclear Gene-Encoded Leigh Syndrome Spectrum Overview.. PMID: 26425749
- 2. Han L et al.. 2026. The tRNA-Derived Fragment tRF-E Promotes Ferroptosis in Hepatocellular Carcinoma to Suppress Tumor Progression.. Cancer Res 86(13):3233-3248 PMID: 41886622
- 3. Darnell AM et al.. 2026. Ribosome-associated quality control of aberrant protein production during amino acid limitation.. bioRxiv PMID: 41648215
- 4. Lazard M et al.. 2000. The tRNA-dependent activation of arginine by arginyl-tRNA synthetase requires inter-domain communication.. J Mol Biol 302(4):991-1004 PMID: 10993737
- 5. Lee SW et al.. 2004. Aminoacyl-tRNA synthetase complexes: beyond translation.. J Cell Sci 117(Pt 17):3725-34 PMID: 15286174
- 6. Mendes MI et al.. 2020. RARS1-related hypomyelinating leukodystrophy: Expanding the spectrum.. Ann Clin Transl Neurol 7(1):83-93 PMID: 31814314
- 7. Cavarelli J et al.. 1998. L-arginine recognition by yeast arginyl-tRNA synthetase.. EMBO J 17(18):5438-48 PMID: 9736621
- 8. Avcilar-Kucukgoze I et al.. 2022. Functional Interplay between Arginyl-tRNA Synthetases and Arginyltransferase.. Int J Mol Sci 23(17) PMID: 36077558
